Hughes W T
J Pediatr. 1984 Oct;105(4):569-75. doi: 10.1016/s0022-3476(84)80421-7.
Hematogenous (disseminated) histoplasmosis occurred in 31 of 4158 children with cancer or immune deficiency disorders. Approximately half of the 31 patients had pulmonary lesions, reacted to the histoplasmin skin test, and generated complement-fixing antibodies to Histoplasma capsulatum. In a comparative study delayed hypersensitivity to histoplasmin was demonstrated in 36 (5.7%) of 634 children at the time of diagnosis of cancer. Patients with cancer who were reactive to histoplasmin before treatment were at no greater, and possibly less, risk for hematogenous histoplasmosis than were nonreactors. All of the 27 patients who received treatment for greater than 1 day recovered; three had recurrences that responded to treatment.
4158例患有癌症或免疫缺陷疾病的儿童中，有31例发生血行播散型组织胞浆菌病。这31例患者中约半数有肺部病变，对组织胞浆菌素皮肤试验有反应，并产生针对荚膜组织胞浆菌的补体结合抗体。在一项对比研究中，634名儿童在癌症诊断时，有36例（5.7%）表现出对组织胞浆菌素的迟发型超敏反应。治疗前对组织胞浆菌素有反应的癌症患者发生血行播散型组织胞浆菌病的风险并不高于无反应者，甚至可能更低。接受治疗超过1天的27例患者均康复；3例复发，但对治疗有反应。
